STOCK TITAN

Abivax Statement on Short Seller Report

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Abivax (ABVX) plans to file a U.S. New Drug Application for obefazimod by the end of 2026.

The company expects data from its Phase 3 ABTECT trials to support the filing with the U.S. Food and Drug Administration. Obefazimod, also known as ABX464, is in Phase 3 development for moderately to severely active ulcerative colitis.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. New Drug Application for obefazimod planned by the end of 2026, supported by Phase 3 ABTECT data

Negative

  • None.

Key Figures

U.S. FDA NDA filing: by the end of the year
U.S. FDA NDA filing
by the end of the year
Abivax says Phase 3 ABTECT results will support the filing

Historical Context

1 past event · Latest: Jul 30
1 event
  1. Jul 30

    FDA interaction

    24h Move
    +0.5%

    FDA feedback aligned with planned obefazimod NDA strategy and end-of-year submission target.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nda, phase 3, ulcerative colitis
3 terms
nda regulatory
"which will support Abivax’s U.S. FDA NDA filing by the end of the year."
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
phase 3 medical
"including the results of our Phase 3 ABTECT trials"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
ulcerative colitis medical
"for the treatment of moderately to severely active ulcerative colitis."
A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google


Abivax Statement on Short Seller Report

PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax,” the “Company,” “we” or “our”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.

We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax’s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax’s U.S. FDA NDA filing by the end of the year.

Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contacts:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

Longacre Square Partners
Abivax@longacresquare.com

Attachment


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Abivax plan to file its U.S. New Drug Application for obefazimod?

Abivax plans to file by the end of 2026. The company expects data from its Phase 3 ABTECT trials to support the application.

Keep reading